Alto Neuroscience’s (ANRO) Outperform Rating Reiterated at William Blair

William Blair reaffirmed their outperform rating on shares of Alto Neuroscience (NYSE:ANRO) in a research report released on Friday morning,RTT News reports. William Blair also issued estimates for Alto Neuroscience’s Q1 2026 earnings at ($0.53) EPS, Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.43) EPS and Q4 2026 earnings at ($0.43) EPS.

Alto Neuroscience Stock Up 0.6 %

ANRO stock opened at $2.71 on Friday. The stock has a 50-day moving average price of $3.63 and a 200-day moving average price of $6.05. Alto Neuroscience has a 1-year low of $2.58 and a 1-year high of $18.35. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 13.09.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.09. Equities research analysts expect that Alto Neuroscience will post -2.54 earnings per share for the current year.

Institutional Trading of Alto Neuroscience

Several large investors have recently made changes to their positions in the company. Wells Fargo & Company MN grew its stake in shares of Alto Neuroscience by 40.0% in the 4th quarter. Wells Fargo & Company MN now owns 10,989 shares of the company’s stock valued at $46,000 after buying an additional 3,139 shares during the period. Deutsche Bank AG grew its stake in shares of Alto Neuroscience by 31.3% in the 4th quarter. Deutsche Bank AG now owns 15,210 shares of the company’s stock valued at $64,000 after buying an additional 3,629 shares during the period. BNP Paribas Financial Markets grew its stake in shares of Alto Neuroscience by 619.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock valued at $49,000 after buying an additional 3,715 shares during the period. Rhumbline Advisers grew its stake in shares of Alto Neuroscience by 24.4% in the 4th quarter. Rhumbline Advisers now owns 25,556 shares of the company’s stock valued at $108,000 after buying an additional 5,008 shares during the period. Finally, Philadelphia Financial Management of San Francisco LLC grew its stake in shares of Alto Neuroscience by 1.5% in the 3rd quarter. Philadelphia Financial Management of San Francisco LLC now owns 449,952 shares of the company’s stock valued at $5,147,000 after buying an additional 6,663 shares during the period.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.